7/13
07:47 am
anro
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Medium
Report
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
7/2
04:13 pm
anro
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? [Yahoo! Finance]
Medium
Report
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? [Yahoo! Finance]
6/17
09:00 am
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright.
Medium
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright.
6/15
08:17 am
anro
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia [Yahoo! Finance]
Medium
Report
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia [Yahoo! Finance]
6/15
08:03 am
anro
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Medium
Report
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
5/28
09:01 am
anro
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors [Yahoo! Finance]
Low
Report
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors [Yahoo! Finance]
5/28
08:03 am
anro
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Low
Report
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
5/27
08:00 am
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright.
Low
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright.
5/22
08:00 am
anro
Alto Neuroscience (ANRO) is now covered by Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Alto Neuroscience (ANRO) is now covered by Wolfe Research. They set an "outperform" rating on the stock.
5/18
10:00 am
anro
Alto Neuroscience (ANRO) was given a new $36.00 price target by Robert W. Baird.
Medium
Report
Alto Neuroscience (ANRO) was given a new $36.00 price target by Robert W. Baird.
5/17
01:01 am
anro
Medium
Report
5/15
08:27 am
anro
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
Low
Report
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
5/14
09:00 am
anro
Alto Neuroscience (ANRO) had its "neutral" rating reaffirmed by Wedbush.
Medium
Report
Alto Neuroscience (ANRO) had its "neutral" rating reaffirmed by Wedbush.
5/13
07:46 am
anro
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights [Yahoo! Finance]
5/13
07:03 am
anro
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
Medium
Report
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
5/11
04:05 pm
anro
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Low
Report
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
5/11
01:51 pm
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
5/9
01:01 am
anro
Low
Report
5/4
08:14 am
anro
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting [Yahoo! Finance]
Low
Report
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting [Yahoo! Finance]
5/4
08:03 am
anro
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
Low
Report
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
4/22
04:06 pm
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
4/21
10:48 am
anro
Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]
Low
Report
Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]
4/21
08:53 am
anro
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]
Medium
Report
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]
4/21
08:03 am
anro
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Medium
Report
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression